Crinetics Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
25.8%projected annual EPS growth
Analyst Coverage
10analysts covering
FY EPS (est.)
-$4.13next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
| Q4 and Full Year 2026 Earnings Release | 25 Feb 2027 |
Monitoring Framework
Key Performance Indicators
PALSONIFY Net Product Revenue Quarterly10.3M
PALSONIFY Patient Enrollment Forms Quarterly232.0
Unique PALSONIFY Prescribing Healthcare Providers Quarterly263.0
Watch Items
- Commercial adoption and payer reimbursement coverage for PALSONIFYTrigger: Reimbursement coverage falling below 70% of treated patientsAction: Re-evaluate commercial sales strategy, payer engagement, and patient assistance programs.
- Clinical trial enrollment and progress for atumelnantTrigger: Delays in initiating or enrolling the Phase 3 CALM-CAH trial or Phase 2/3 EQUILIBRIUM studyAction: Assess clinical site performance, expand geographic reach of trial sites, and adjust R&D budget allocations.
- Quarterly cash burn rate and operating expensesTrigger: Full-year GAAP operating expenses exceeding the guided range of $600 million to $650 millionAction: Implement cost-containment measures across non-essential R&D programs and optimize SG&A commercial spend.
Research as of 19 Jun 2026